In a news release, specialty life sciences companyRevive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS), which focuses on developing therapeutics for infectious diseases and rare disorders, announced that it has executed a non-binding letter of intent (LOI) to acquire the full intellectual property (IP) rights pertaining to the psilocybin assets owned by PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corp. (PHRM:CSE; PHRRF:OTC Pink).
The firm noted that PharmaTher is a specialty life sciences company engaged in researching and developing psychedelic pharmaceuticals and it activities involve the discovery of novel applications for psychedelic medicines like psilocybin and ketamine combined with U.S. FDA-approved drugs for treating depression and pain and neurological related disorders such as Parkinson's disease and other movement disorders.
The company mentioned that purchase of PharmaTher's IP portfolio comes after its prior announcement stating that the two companies had agreed to partner together on an exclusive research collaboration formed to advance the development of psilocybin for cancer treatments and to investigate new applications for certain undisclosed psychedelic compounds.
The firm stated that the acquired assets will include all IP and work derived from PharmaTher's pre-clinical research activities in traumatic brain injury and stroke, all IP pertaining to neurological disorders, cancers and novel combinations of psilocybin and FDA approved drugs and all work and IP derived from a study being currently undertaken by the National Health Research Institute in Taiwan.
Revive will also gain the rights for key provisional patent applications with the U.S. Patent and Trademark Office, which apply to the use of psilocybin in the treatment of neurological brain injuries and migraines, the treatment of liver carcinoma, melanoma, breast neoplasms, Kidney neoplasms and acute myeloid leukemia and for novel combinations of certain FDA approved drugs with psilocybin to treat neurological disorders.
Revive Therapeutics' CEO Michael Frank remarked, "Our psychedelics pharmaceutical program has been predominantly focused on the development and evaluation of our novel orally dissolvable thin film strip for psilocybin, and with the acquisition of PharmaTher's proprietary psilocybin platform it will complement our objectives in commercializing a unique prescription-based psilocybin product for neurological disorders and FDA orphan drug indications."
"PharmaTher discovers novel uses of psychedelic pharmaceuticals, such as psilocybin, and combinations with FDA-approved drugs for development internally or with pharmaceutical partners, such as Revive, which has a unique oral drug delivery system to complement our psilocybin development program...I am pleased that we have found a home for our psilocybin program which will allow us to solely focus our resources on our clinical-stage product pipeline with FDA-approved ketamine to treat neurological disorders, such as Parkinson's disease and movement disorders, depression and pain," stated PharmaTher's CEO Fabio Chianelli.
Revive stated that it will proceed with its due diligence investigation and after that time the final terms of the acquisition will be detailed in a definitive agreement. The company expects that the transaction will close on or before Jan. 31, 2021, subject to ordinary closing conditions and the execution of an agreed upon definitive agreement.
Read what other experts are saying about:
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: Revive Therapeutics. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
